`
`Application No. 15/121,623
`
`- 3 -
`
`GEUIJEN er a].
`
`Amendments to the Claims
`
`This listing of claims will replace all prior versions, and listings, of claims in the application.
`
`1.
`
`(Currently Amended) A bispecific antibody comprising a first binding arm that binds
`
`domain 1 of human erb-b2 receptor tyrosine kinase 2 (ErbB-2) and comprises the CDR1,
`
`CDR2 and CDR3 se uences of the MF3958 heav chain variable re ion amino acid
`
`se uences AYYIN SE ID NO:49 RIYPGSGYTSYA KF
`
`SE ID N050 and
`
`PPVYYDSAWFAY g SEQ ID NO:51), respectively), and a second binding arm that binds
`
`domain III of human erb-b2 receptor tyrosine kinase 3 (ErbB-3) and comprises the CDRl,
`
`CDR2 and CDR3 se uences of the MF3178 heav chain variable re ion amino acid
`
`se uences GYYMH SE ID NO:64 WINPNSGGTNYA KF G SE IDNO:65 and
`
`
`
`2.
`
`(Currently Amended) The bispecific antibody of claim 1, wherein the antibody reduces
`
`ligand—neuregulin-induced or heregulin-induced growth of an ErbB-2 and ErbB-3 positive
`
`cell.
`
`3.
`
`(Previously Presented) The bispecific antibody of claim 2, wherein the cell has at least
`
`100,000 copies of ErbB-2 on its surface.
`
`4.
`
`(Currently Amended) The bispecific antibody of claim [[1]] 2, wherein the cell is a human
`
`breast cancer MCF-7 cell, a human breast cancer SKBR-3 cell, a human gastric NCI-N87
`
`cell, a human pancreatic adenocarcinoma BXPC-3 cell, a human breast cancer BT-474 cell
`
`or a human breast cancer JIMT-1 cell.
`
`5.
`
`(Canceled)
`
`6.
`
`(Currently Amended) The bispecific antibody of claim [[1]] 2, wherein the second binding
`
`arm interferes with binding of an ErbB-3 ligand to ErbB-3.
`
`Atty. Dkt. No. 4096.0100002/DAS/PAC/PMR
`
`